Lung Cancer

Anti-EGF drug shrinks tumors, relieves symptoms

Published in Cancer Weekly, July 9th, 2002

by Janis Kelly, senior medical writer - Locking a tyrosine kinase up inside cancer cells can help stabilize disease and relieve symptoms even in very advanced, treatment-refractory lung cancer.

Mark G. Kris, MD, reported that tumors shrank by half in more than 10% of patients and stabilized in another third following treatment with gefitinib (also known as Iressa or ZD1839). The new drug also reduced symptoms such as shortness of breath, poor appetite, cough, and weight loss in 36% of patients.

"This shows that giving a drug that locks an enzyme up in the cell makes patients feel better. That's amazing." said Kris, who is chief of the thoracic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-07-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry